A CML Patient Weighs in on an "Area of Confusion"

News
Article

An issue causing a lot of confusion among oncologists and their patients is Polymerase Chain Reaction (PCR) testing, and specifically, how the results are reported and interpreted.

I'd like to suggest a topic for discussion that is causing a lot of confusion among oncologists and their patients: Polymerase Chain Reaction (PCR) testing, and specifically, how the results are reported and interpreted. This may sound like a mundane issue, but oncologists are being confused by changes in PCR test reporting, which is leading them to inadvertently giving their patients negatively skewed prognoses. I have seen this many times on the L&LS Discussion Board "Living with CML Leukemia". 

PCR testing has been used for years to determine remission status (or lack of) in leukemia patients. Labs around the world have used different equipment and standards, so PCR results have not been considered comparable between labs. In the past few years there has been a move to standardize PCR reporting for CML leukemia based on an "International Standard" for log reductions.

As this changeover is in the middle of implementation, it is causing confusion since there are many oncologists who do not understand the changeover. So, many patients are also being confused, and even told they are losing remission status, when it is simply the new reporting that has changed the numbers.

Recent Videos
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.